Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis Patients With Translocation (11;14): A Multicenter Phase 2 Study
Latest Information Update: 10 Jun 2025
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Venetoclax (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
Most Recent Events
- 22 Jan 2025 Status changed from not yet recruiting to recruiting.
- 11 Oct 2024 New trial record